Plasma fibrinolytic activity following oral anabolic steroid therapy.

Thromb Diath Haemorrh. 1975 Sep 30;34(1):236-45.

Plasma fibrinolytic activity following oral anabolic steroid therapy.

Walker ID, Davidson JF, Young P, Conkie JA.

Six anabolic steroids were assessed for their ability to enhance plasma
fibrinolytic activity in males with ischaemic heart disease. Five
17alpha-alkylated steroids (Ethyloestrenol, Norethandrolone, Methandienone,
Methylandrostenediol and Oxymetholone) were examined and all produced a
significant increase in plasma plasminogen activator as measured by the
euglobulin lysis time. The only non-17alpha-alkylated steroid studied
(Methenolone acetate) failed to enhance fibrinolysis. The 17alpha-alkylated
steroids studied all deserve more detailed evaluation of their long term effects
on plasma fibrinolytic activity.

Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias.

Scand J Haematol. 1986 Apr;36(4):346-52.

Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias

[No authors listed]

ABSTRACT: A prospective randomized study of androgen therapy in aplastic anaemia (AA) was performed: 2 androgens (fluoxymesterone and norethandrolone) at high (1 mg/kg/d) and low (0.2 mg/kg/d) dose were studied on 110 patients; and 4 androgens given at high doses were objectively compared in 125 other cases. When patients are matched for AA severity there is an obvious efficiency of the high-dose androgens in the survival of the less severe cases of aplastic anaemia and in their haematological improvement. The data further show that, among the 4 androgens tested, fluoxymesterone is the most efficient and stanozolol the least. We conclude that androgen therapy is truly efficient in moderately severe aplastic anaemia and that fluoxymesterone (1 mg/kg/d) for 18 months should be chosen as reference drug to any new androgen therapy assay